Company / R&D Expense
Moleculin Biotech, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$17.7M
FY2025
5-year range
$12.8M / $19.5M
FY2021-FY2025
Trend
-9.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $19M to $18M over the past 2 years.
Based on SEC 10-K filings.
$18M in FY2025 with a 5-year CAGR of +10.0%.
Declined from $19M to $18M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +7.1%
- 5-Year CAGR
- +10.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +10.0%, indicating consistent growth.
- In FY2025, r&d expense decreased 9.0% year-over-year.
- Peak r&d expense was recorded in FY2024.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.7M | -9.0% |
| FY2024 | $19.5M | +2.7% |
| FY2023 | $19.0M | +31.6% |
| FY2022 | $14.4M | +13.0% |
| FY2021 | $12.8M | +15.8% |
| FY2020 | $11.0M | +13.2% |
| FY2019 | $9.7M | +114.0% |
| FY2018 | $4.5M | +203.8% |
| FY2017 | $1.5M | +474.5% |
| FY2016 | $260.4K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026